Critical Contrast: DBV Technologies (NASDAQ:DBVT) vs. Genenta Science (NASDAQ:GNTA)

DBV Technologies (NASDAQ:DBVT) and Genenta Science (NASDAQ:GNTA) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, earnings, dividends, institutional ownership, profitability, analyst recommendations and risk.

Valuation and Earnings

This table compares DBV Technologies and Genenta Science”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DBV Technologies	$15.73 million	5.02	-$72.73 million	($4.50)	-0.85
Genenta Science	N/A	N/A	-$12.60 million	N/A	N/A

Genenta Science has lower revenue, but higher earnings than DBV Technologies.

Profitability

This table compares DBV Technologies and Genenta Science’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
DBV Technologies	-815.73%	-106.07%	-76.17%
Genenta Science	N/A	N/A	N/A

Analyst Recommendations

This is a summary of recent ratings and recommmendations for DBV Technologies and Genenta Science, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DBV Technologies	0	0	2	0	3.00
Genenta Science	0	0	1	0	3.00

DBV Technologies presently has a consensus price target of $22.50, indicating a potential upside of 485.94%. Genenta Science has a consensus price target of $25.00, indicating a potential upside of 371.70%. Given DBV Technologies’ higher possible upside, analysts plainly believe DBV Technologies is more favorable than Genenta Science.

Insider & Institutional Ownership

71.7% of DBV Technologies shares are owned by institutional investors. Comparatively, 15.1% of Genenta Science shares are owned by institutional investors. 1.9% of DBV Technologies shares are owned by company insiders. Comparatively, 29.0% of Genenta Science shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Volatility & Risk

DBV Technologies has a beta of 0.64, suggesting that its stock price is 36% less volatile than the S&P 500. Comparatively, Genenta Science has a beta of 0.74, suggesting that its stock price is 26% less volatile than the S&P 500.

Summary

Genenta Science beats DBV Technologies on 6 of the 10 factors compared between the two stocks.

About DBV Technologies

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis. The company’s earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

About Genenta Science

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. In addition, it develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. Genenta Science S.p.A. was incorporated in 2014 and is headquartered in Milan, Italy.